The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES)  by Kjøller-Hansen, Lars et al.
CLINICAL STUDIES Cardiac Surgery
The Angiotensin-converting Enzyme
Inhibition Post Revascularization Study (APRES)
Lars Kjøller-Hansen, MD, Rolf Steffensen, MD, Peer Grande, MD, PHD
Copenhagen, Denmark
OBJECTIVE This study was performed to assess the effect of treatment with ramipril on the incidence of
cardiac events after invasive revascularization in patients with asymptomatic moderate left
ventricular dysfunction.
BACKGROUND In patients with angina pectoris and left ventricular dysfunction, both invasive revasculariza-
tion and treatment with angiotensin-converting enzyme inhibitors reduce cardiac mortality
and morbidity. Whether there is a benefit from combining the two treatment strategies has
never been evaluated prospectively.
METHODS After invasive revascularization, 159 patients with preoperative chronic stable angina pectoris,
left ventricular ejection fraction between 0.30 and 0.50 and no clinical heart failure were
randomly assigned to receive double-blind treatment with either ramipril or placebo and
subsequently followed for a median of 33 months.
RESULTS Ramipril reduced the incidence of the triple-composite end point of cardiac death, acute
myocardial infarction or clinical heart failure (risk reduction 58%; 95% confidence interval 7%
to 80%, p 5 0.031). The incidence of the quadruple-composite end point of cardiac death,
acute myocardial infarction, clinical heart failure or recurrent angina pectoris was not altered
with ramipril. These findings were consistent across subgroups with respect to left ventricular
ejection fraction below or above 0.40, and whether coronary artery bypass grafting or
percutaneous transluminal coronary angioplasty was performed.
CONCLUSIONS In patients with angina pectoris and asymptomatic moderate left ventricular dysfunction,
long-term treatment with ramipril after invasive revascularization significantly reduced the
incidence of the composite end point of cardiac death, acute myocardial infarction or clinical
heart failure, indicating that the beneficial effects of angiotensin-converting enzyme inhibitor
treatment may be extended to include treatment of this patient group. (J Am Coll Cardiol
2000;35:881–8) © 2000 by the American College of Cardiology
Patients with ischemic heart disease and reduced left ven-
tricular ejection fraction (LVEF ) have an adverse prognosis
with respect to cardiac mortality and morbidity (1–5).
Although invasive revascularization improves prognosis in
patients with severe angina pectoris and LVEF below 0.50
(1,3,5), these patients still have a worse prognosis than
patients with normal LVEF.
Treatment with angiotensin-converting enzyme inhibitor
(ACE-I) improves survival and reduces the incidence of
cardiac events in patients with left ventricular dysfunction in
many circumstances (6–9). However, extrapolation of the
results of the major ACE-I trials (6–9) to apply to the
sizable population of patients with asymptomatic and only
moderate left ventricular dysfunction undergoing invasive
revascularization for chronic stable angina pectoris is as yet
not justified based on evidence. First, ACE-I should be used
with caution in patients with severe angina pectoris (10–
12). Second, Studies of Left Ventricular Dysfunction
(SOLVD) prevention trial failed to show survival benefit
with ACE-I treatment, and the morbidity benefit in the
same study was confined to patients with lower LVEF
fractiles (6,13). Finally, invasive revascularization improves
prognosis per se (2,3,14).
Accordingly, the present study was designed to assess
whether treatment with ramipril reduces cardiac mortality
and cardiac morbidity in patients with asymptomatic mod-
erate left ventricular dysfunction undergoing invasive revas-
cularization for chronic stable angina pectoris
METHODS
The Angiotensin-converting Enzyme Inhibition Post Re-
vascularization Study (APRES) was a randomized, double-
blind placebo-controlled monocenter study carried out at
the Heart Center, Rigshospitalet, Copenhagen, Denmark.
The study was approved by the local Ethics Committee
From The Heart Center, Rigshospitalet, Copenhagen, Denmark.
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(02-149/93) and the National Board of Health (5312-291-
1993). Patients undergoing coronary angiography were
found eligible if they were aged 18 to 75 years, had no prior
cardiac surgery, had LVEF between 0.30 and 0.50 as
determined by ventriculography or echocardiography and
were referred for invasive revascularization with coronary
artery bypass grafting (CABG) or percutaneous translumi-
nal coronary angioplasty (PTCA) for angina pectoris after
coronary angiography and clinical evaluation. Patients ex-
cluded from the study were those with a history of recent
acute myocardial infarction (AMI) (,3 months) and/or
clinical heart failure, i.e., history of dyspnoea relieved by
diuretic therapy, ongoing ACE-I treatment due to evi-
denced indications, concomitant valvular disease or geo-
graphic restrictions to complete follow-up. Other exclusion
criteria were participation in another investigational drug
trial, known intolerance to ACE-I therapy, childbearing
potential and medical conditions (including periprocedural
complications) that could have major influence on outcome
or known to contraindicate use of the test drug.
Design. The design of the study has previously been
presented (15). After uncomplicated invasive revasculariza-
tion, eligible patients were enrolled in the study after giving
written consent. A test dose of ramipril 2.5 mg was given
and, if tolerated, patients were assigned randomly to
ramipril 5 mg o.d. or matching placebo according to a
computer-generated assignment scheme in blocks of four
(two ramipril, two placebo), and with stratification accord-
ing to type of invasive revascularization (CABG or PTCA).
Study drug treatment was commenced immediately after
randomization. The intended randomization time was five
to seven days after CABG, and one to two days after
PTCA. The ramipril dose was increased to 10 mg o.d or
matching placebo after one month. If this dose was not
tolerated, patients were given the highest tolerable dose.
Follow-up. Follow-up visits were scheduled at one, three
and six months after randomization and every six months
thereafter. Patients were instructed to contact the study
physicians between scheduled visits in case of health-related
problems. A median follow-up time of 2.5 years was
intended with a minimum follow-up of one year. At each
visit, occurrence of any study outcome, use of medication,
adverse events and patient compliance with the test drug
were recorded.
End points. The main outcome measures were time to
cardiac events. The primary end points were the composite
quadruple end point of cardiac death, AMI, development of
clinical heart failure or recurrent angina pectoris; and the
composite triple end point of cardiac death, AMI or
development of clinical heart failure. The limited number of
potentially eligible patients at our disposal necessitated the
use of composite end points. Thus, the triple-composite end
point was constituted of single events on which ACE-I
previously had shown benefit, i.e., cardiac death, AMI and
heart failure. The quadruple-composite end point addition-
ally included recurrent angina pectoris as a clinical expres-
sion of an anti-ischemic and antiatherosclerotic efficacy.
Several secondary end points were predefined. These
were double composite end points of cardiac death and
AMI, or cardiac death and development of clinical heart
failure, and the following single events: mortality due to all
causes, cardiac death, development of clinical heart failure,
AMI and recurrent angina pectoris.
For patients who died, dates of death were obtained from
the Danish Central Person Registry. Causes of death were
acquired from hospital records and/or personal interview
with relatives. Determination and classification of causes of
death were made by the investigators before the treatment
allocation code was broken. In patients who suffered AMI
during the study period, the diagnosis was confirmed from
hospital records. Development of clinical heart failure was
defined as the need for open ACE-I treatment, use of
diuretics for clinical heart failure as judged by a study
physician or hospitalization for heart failure. Recurrent
angina pectoris was defined as the need for antianginal
drugs for angina pectoris and/or angina pectoris of at least
Canadian Cardiovascular Society functional class II in a
patient initially free of angina after revascularization. A
discussion of the relevance of the end points has been
presented previously (15). Furthermore, substudies were
carried out, including an echocardiographic study, exercise
stress testing and quality of life (15).
Statistics. Based on an expected cumulative event rate of
30% and a reduction in cardiac events of 40% during
ramipril treatment, a significance level of 5% and a power of
80%, power calculation revealed that a sample size of 400
patients was required.
Statistical analyses were carried out using Statistica for
Windows version 5.1 software (StatSoft Inc, Tulsa, OK).
Analyses were carried out according to the principle of
intention to treat, and all p values were two sided. Kaplan-
Meier estimates of time from randomization to event of
interest were computed, and log-rank test was used for
comparison of the two treatment groups, ramipril and
placebo. For composite end points, only the first occurrence
of any end point was counted in the study. The relative risk
Abbreviations and Acronyms
4S 5 Scandinavian Simvastatin Survival Study
ACE-I 5 angiotensin-converting enzyme inhibitor
AMI 5 acute myocardial infarction
APRES5 Angiotensin-converting Enzyme Inhibition
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CASS 5 coronary artery surgery study
LVEF 5 left ventricular ejection fraction
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was calculated as a hazard ratio and the percent risk
reduction was calculated as (1 2 relative risk). Continuous
and categorical variables were compared with unpaired t
tests and chi-square tests, respectively.
To ascertain the uniformity of the effects with ramipril
treatment across the patient population, univariate and
multivariate Cox proportional hazard regression analyses
were carried out with end points as dependent variables. As
explanatory variables were selected: treatment group,
CABG versus PTCA, LVEF (baseline ejection frac-
tion .0.40 or #0.40), triple-vessel disease, complete revas-
cularization, anterior Q waves on electrocardiogram at
randomization, use of beta-blockers, use of calcium-
antagonists, history of hypertension, diabetes mellitus,
smoking, age ($65 or ,65 years), and gender. Two
multivariate models were carried out using explanatory
variables that turned out as significant predictors in the
univariate model; and additionally forcing age, hyperten-
sion, diabetes mellitus, gender, type of revascularization and
LVEF into the model.
Numbers needed to treat (NNT) were calculated as
1/(frequency of event in placebo group 3 risk reduction),
which corresponds to 1/(frequency of event in placebo
group 2 frequency of event in treatment group).
RESULTS
From February 1, 1994 to October 15, 1996, nearly 3,000
consecutive patients undergoing coronary angiography were
screened. Despite a lower inclusion rate than estimated, it
was decided to end study recruitment period after 32
months. A total of 213 patients were found eligible and 159
patients were randomized, 130 after CABG and 29 after
PTCA. Study drug treatment was commenced at a median
interval from invasive revascularization of seven and six days
for the ramipril and placebo groups, respectively. At the end
of the study, the vital status was available for all randomized
patients. Among the enrolled patients, the survivors were
followed for a median of 33 months (range 12 to 46
months). The baseline characteristics of patients in the two
treatment groups are presented in Table 1.
Primary end points. Results of the main outcome mea-
sures are presented in Table 2, and time to cardiac event
curves for each treatment group are presented in Figures
1–3. The quadruple composite end point of cardiac death,
nonfatal AMI, development of heart failure or recurrent
angina pectoris was reached in 36 patients in the ramipril
group and in 41 in the placebo group (p 5 0.63). With
respect to the triple composite end point, eight patients in
the ramipril group suffered cardiac death, nonfatal AMI or
developed heart failure compared with 18 in the placebo
group (p 5 0.031). The time to cardiac event curves
diverged early and continued to diverge for the triple
composite end point (Fig. 2).
Secondary end points. Results regarding the secondary end
points are presented in Table 2 and Figure 3. The causes of
deaths in the two treatment groups are presented in Table 3.
There were two deaths (2.5%) in the ramipril group and eight
in the placebo group (10%) (p 5 0.053). There was a
significant reduction in the prespecified secondary end point of
cardiac death with ramipril treatment (p 5 0.032). All cardiac
deaths were classified as sudden death/fatal AMI (being
sudden ischemic or sudden arrhythmic), including one patient
who died within 6 h of onset of symptoms of AMI. Six cardiac
deaths were out of hospital. In only one patient, cardiac death
was related to progressive heart failure.
There were no significant differences between groups
with respect to AMI or development of angina pectoris
(Table 2). Twelve patients in the ramipril group were
hospitalized with chest pain on suspicion of unstable angina
pectoris compared with nine in the placebo group (p 5
0.50). All cases of nonfatal AMI were non-Q-wave. Among
the five patients who suffered AMI, two subsequently died
and 2 developed heart failure. With respect to development
of heart failure, 6 patients in the ramipril group and 12 in
the placebo group developed heart failure (p 5 0.10), while
two patients in the ramipril group and 5 patients in the
placebo group were hospitalized for heart failure (p 5 0.23).
The 18 patients who developed heart failure were followed
for a median period of 19 months after this incident. Yet,
only one patient developed persistent severe heart failure,
i.e., New York Heart Association functional class III,
despite medical treatment, and only this single patient died
after development of heart failure.
Multivariate analyses. For the quadruple composite end
point, LVEF # 0.40 was the single independent predictor
of an adverse outcome. The relative risk (95% confidence
interval [CI]) with LVEF # 0.40 was 1.63 (1.04 to 2.56).
For the triple composite end point, treatment group and
LVEF # 0.40 were independent predictors of an adverse
outcome. The relative risk with ramipril treatment was 0.39
(95% CI 0.16 to 0.90). The relative risk (95% CI) with
LVEF # 0.40 was 3.29 (1.48 to 7.28).
Forcing age, gender, diabetes mellitus, hypertension, type
of revascularization and LVEF into the multivariate model
gave similar results. In this model, the relative risks with
ramipril treatment were 0.91 for the quadruple composite
end point (95% CI 0.58 to 1.42, p 5 0.67), and 0.38 for the
triple composite end point (95% CI 0.16 to 0.88, p 5 0.024).
Compliance with treatment, withdrawals, adverse events,
effects on blood pressure and concurrent medication. All
patients tolerated the test dose. The target dose of 10 mg
ramipril once daily or matching placebo was reached in 90%
of patients in the ramipril group and in 96% in the placebo
group. At the end of the study, 85% in the ramipril group
were on study drug compared with 84% in the placebo
group. Reasons for withdrawal from treatment with the test
drug were open-label ACE-I treatment (five ramipril, seven
placebo), loss of consent or lost to follow-up (five ramipril,
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four placebo), side effects (two ramipril, two placebo) and
endocarditis requiring surgery (one ramipril).
No patients developed renal impairment or electrolytical
derangement. Thirty patients in the ramipril group, com-
pared with 27 in the placebo group, experienced minor
adverse events, the most frequent being tiredness, gastroin-
testinal disturbances, dizziness and cough. A tendency
towards a higher frequency of coughing, tiredness and
dizziness in the ramipril group was found. From three
months and beyond, the mean systolic and mean diastolic
blood pressures were lower with ramipril than with placebo
(128/75 vs. 136/81 at one year, p , 0.05), whereas the mean
heart rates were equal (70 vs. 70 beats/min). The use of
concurrent cardiovascular drugs was similar in the two
treatment groups (Table 4). Four of the seven cases of
sudden death/fatal AMI occurred during beta-blocker ther-
apy. The use of diuretics reflects treatment for hypertension
and the frequent administration of diuretics in the early
phase after CABG due to volume overload postoperatively.
After publication of the Scandinavian Simvastatin Survival
Study (4S), patients were given lipid-lowering drugs accord-
ing to the 4S criteria (16). The mean p-cholesterol values at
one year were 5.7 mmol/liter for the ramipril group and 5.9
mmol/liter for the placebo group.
DISCUSSION
In the present study, we found that in patients with
asymptomatic and moderate left ventricular dysfunction
undergoing invasive revascularization for chronic stable
angina pectoris, long-term treatment with ramipril, initiated
shortly after invasive revascularization, reduced the inci-
Table 1. Baseline Characteristics of Patients in the Two Treatment Groups
Characteristic
Ramipril
(n 5 80)
Placebo
(n 5 79)
Mean age (years) 61.4 60.6
Male gender (%) 88 90
Mean body mass index (kg/m2) 27.1 27.2
Hypertension (%) 25 29
Diabetes mellitus (%) 9 9
Smoker (past or current) (%) 83 88
Mean duration of history of angina pectoris (years) 3.7 3.4
AMI by history (%) 76 77
Mean interval since last AMI (years) 2.9 2.5
ECG
Anterolateral Q wave (%) 29 38
Inferoposterior Q wave (%) 57 52
Both (%) 8 10
LBBB (%) 3 4
Mean left ventricular ejection fraction (%)
Ventriculography 44.7 44.9
Echocardiography 41.4 42.8
Extension of coronary artery disease
I/II/III (%) 14/25/61 16/39/45
LMA (%) 19 8
LAD stenosis: patients who underwent CABG (%) 95 88
LAD stenosis: patients who underwent PTCA (%) 47 50
Complete revascularized (%) 85 86
Mean blood pressure systolic/diastolic (mm Hg) 129/79 130/78
Mean heart rate (beats/min) 82 79
Plasma cholesterol (mmol/liter) 6.3 6.5
Medication at randomization (%)
Beta-blockers 31.3 29.1
Ca-antagonists 7.5 12.6
Diuretics 20.0 22.8
Digoxin 12.5 7.5
Aspirin 100 100
Statins 26.2 34.1
No significant differences were observed for any comparisons between the ramipril and placebo treatment groups, with the
exception of frequency of triple-vessel disease and LMA disease.
I/II/III denotes single-, double-, triple-vessel disease. AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass
grafting; ECG 5 electrocardiogram; LAD 5 left anterior descending artery; LBBB 5 left bundle branch block; LMA 5 left
main artery disease; PTCA 5 percutaneous transluminal coronary angioplasty.
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dence of the triple composite end point of cardiac death,
AMI and development of clinical heart failure (Table 2 and
Fig. 2). In contrast, with the quadruple composite end point
including recurrent angina pectoris, the study showed no
significant benefit with ramipril therapy (Fig. 1). This
finding may be attributed to a higher although not signifi-
cant incidence of recurrent angina pectoris, observed in the
ramipril group mainly during the first six months (Fig. 3d).
Among the single events that constituted the triple
composite end point, ramipril significantly reduced the
incidence of cardiac death, whereas the reduction in clinical
heart failure and AMI was not significant (Table 2).
However, in interpreting nonsignificance of the single
events, one should bear in mind that the design and power
of the study prescribed the use of composite end points.
The multivariate analysis revealed that the benefit with
ramipril therapy on cardiac death and the triple-composite
end point was not confined to patients with LVEF # 0.40,
as treatment group was an independent predictor. Likewise,
the benefit was consistent according to whether patients
were included after CABG or PTCA. The risk reduction
with ramipril persisted over time as the cumulated event rate
continued to diverge during follow-up time (Fig. 2). The
risk reduction with ramipril treatment was substantial, but
should be seen in the light of a wide CI due to the limited
number of patients in the study. Nevertheless, the lower
95% CI limit of the risk reduction was comparable with that
of larger studies (6,7). Also, the upper 95% CI of NNT with
regard to the triple-composite end point was found within
reasonable clinically relevant limits: 62 patients treated for
two and a half years (Table 2).
Table 2. Incidence and Risk Reduction in Cardiac Events According to Treatment Group
End Point
Number of Patients
% Risk Reduction
(95% CI)
NNT
(95% CI)
p
Value
Ramipril
(n 5 80)
Placebo
(n 5 79)
Quadruple composite 36 41 10 (241–43) — 0.63
Triple composite 8 18 58 (7–80) 8 (5–62) 0.031
Double composite
Cardiac death or AMI 2 9 78 (12–92) 11 (9–73) 0.034
Cardiac death or heart failure 7 17 61 (11–92) 8 (5–42) 0.024
Single events
Cardiac death 1 7 86 (14–95) 13 (11–80) 0.032
AMI 1 4 — — 0.21
Heart failure 6 12 40 (218–82) — 0.10
Recurrent angina pectoris 34 30 219 (290–37) — 0.23
Quadruple-composite end point: cardiac death, AMI, clinical heart failure or recurrent angina pectoris. Triple-composite end point: cardiac death, AMI or clinical heart failure.
For composite end points, only the first occurrence of any end point was counted. — 5 not relevant calculation; AMI 5 acute myocardial infarction; NNT 5 number of patients
to treat for two and a half years with ramipril to prevent one patient from reaching end point.
Figure 1. Cardiac death, AMI, clinical heart failure or recurrent
angina pectoris. Kaplan-Meier plot of time to first event for the
quadruple-composite end point: cardiac death, AMI, heart failure
or recurrent angina pectoris. Shown are the number of patients at
risk in each treatment group at the beginning of each treatment
year.
Figure 2. Cardiac death, AMI or clinical heart failure. Kaplan-
Meier plot of time to first event for the triple-composite end point:
cardiac death, AMI or clinical heart failure. Shown are the number
of patients at risk in each treatment group at the beginning of each
treatment year.
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Comparisons and dissimilarities to other studies. De-
spite obvious differences in inclusion criterions compared
with other ACE-I trials (6–10,17–22), the efficacy of
ACE-I treatment found in the present study falls in line
with previous findings. Thus, in previous studies, ACE-I
therapy was followed by reductions in just cardiac death,
clinical heart failure and AMI (6–9,17), whereas treatment
with ACE-I failed to prevent restenosis, atherosclerosis and
recurrent angina pectoris after PTCA in the short term (18)
as well as in the long term (19). Likewise, the effects of
ACE-I treatment on stable angina pectoris were found to be
variable (20–22) and even harmful (10) in previous clinical
trials. Thus, with respect to symptomatic angina pectoris,
clinical application of the theoretical antiatherosclerotic and
Figure 3. Secondary end points. Kaplan-Meier plot of time to: (a) cardiac death or AMI, (b) cardiac death or heart failure, (c) clinical heart
failure and (d) recurrent angina pectoris.
Table 3. Causes of Death in Study Patients According to Treatment Group
Number of Patients
% Risk Reduction
(95% CI)
p
Value
Ramipril
N 5 80
Placebo
N 5 79
All deaths 2 8 76 (21–92) 0.053
Cardiovascular* 1 8 88 (24–94) 0.018
Cardiac death 1 7 86 (14–95) 0.032
Sudden death/fatal AMI†
Without progressive heart failure 1 6 84 (23–95) 0.054
Sudden death
With progressive heart failure 0 1 — —
Stroke 0 1 — —
Noncardiovascular‡ 1 0 — —
*Cardiovascular death includes cardiac death and fatal stroke. †One case of fatal AMI within 6 h of onset of symptoms.
‡Esophageal cancer. — 5 not relevant; AMI 5 acute myocardial infarction.
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anti-ischemic properties of ACE-I has as yet been disap-
pointing.
The mechanism by which ACE-I reduces cardiac death is
a matter of debate (23). The reduction in cardiac death
without preceding clinically recognized heart failure, which
we observed in the present study, supports the hypothesis
that ACE-I treatment reduces cardiac death not only by
preventing development and progression of clinical recog-
nized heart failure, but probably additionally by reducing
sudden death. The fact that the study population in
APRES, compared with study populations in previous
ACE-I trials (6–9), were less prone to develop severe heart
failure may have revealed and accentuated this efficacy.
The finding of a reduction in sudden death and AMI but
not in recurrent angina pectoris may seem counter-intuitive.
However, this finding is in concordance with some previous
findings (8), and differences in the mechanisms behind
development of these conditions can be emphasized. Sud-
den death in a patient with documented ischemic heart
disease is likely to be due to sudden ischemic or arrhythmic
events (23). Neurohormonal modulation by ACE-I may
reduce sudden vasoconstriction and arrhythmogenesis. In
contrast, recurrent angina pectoris may be due to graft
atherosclerosis, myointimal proliferation and reduction in
perfusion pressure in patients with multiple coronary artery
stenoses.
Acute myocardial infarction, severe angina pectoris, left
ventricular dysfunction and clinical heart failure are definite
risk factors in patients with ischemic heart disease. Previous
ACE-I trials focused on patients with these conditions. In
contrast, the patients included in APRES had no recent
AMI and underwent uncomplicated invasive revasculariza-
tion for chronic stable angina pectoris, the mean LVEF was
0.41 compared with 0.25 to 0.31 in other studies (6,7,9,13)
and the patients included had no clinically recognized heart
failure and were not on diuretic therapy for heart failure.
Taking only these risk factors in account, the study popu-
lation in APRES could be regarded as being at rather low
risk compared with the study populations in previous
ACE-I trials (6–9). However, the incidence of severe
cardiac events in the placebo group in the APRES was not
negligible. Compared with the study populations in other
ACE-I trials, the study population in APRES may have had
risk factors of more extended coronary artery disease and a
longer history of ischemic heart disease. The fact that the
event rate in the placebo group in APRES is representative
for the studied population is supported by the fact that the
risk of cardiac death and AMI found in APRES is similar to
the risk found for surgical patients with ejection fraction
, 0.50 in the Coronary Artery Surgery Study (CASS) (2).
Clinical implications. The findings in APRES support
the fact that patients with asymptomatic and only moderate
left ventricular dysfunction who underwent uncomplicated
invasive revascularization for chronic stable angina pectoris
still carry a significant risk of cardiac death and other cardiac
events (2,4). However, the results in APRES indicate that
long-term treatment with ramipril may reduce this risk.
Accordingly, the benefits with ACE-I treatment may be
extended to include and recommend treatment of this
patient group.
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